WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 2 | 3 ||

14.01.07 ...

-- [ 4 ] --

80. Goverdhan SV, Ennis S, Hannan SR et al. Interleukin-8 promoter polymorphism A/T is a risk factor for age-related macular degeneration // Br J Ophthalmol. Vol. 92, 4. P. 448-450.

81. Grossniklaus HE, Miskala PH, Green WR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7 // Arch Ophthalmol. - 2005. - Vol.

123. - P. 914 921.

82. Grover S1, Murthy RK, Brar VS et al. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography // IOVS. 2010.

Vol. 51, 5. P. 2644-2647.

83. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date // Surv Ophthalmol. - 2006. Vol. 51, 4. - P. 316-363.

84. Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1_CFH) predisposes individuals to agerelated macular degeneration // Proc Natl Acad Sci USA. - 2005. Vol. 102. P.

7227-7232.

85. Handa JT. How does the macula protect itself from oxidative stress? // Mol Aspects Med. 2012. Vol. 33, 4. P. 418-435.

86. Hart SN, Zhong XB. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity // Expert Opin Drug Metab Toxicol. - 2008. - Vol. 4, 4. - P. 439-452.

87. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer // J Clin Oncol. - 2006. Vol. 24, 26.- P. 4236-4244.

88. Holliday EG, Smith AV, Cornes BK et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis // PLoS One. - 2013. - Vol. 8, 1. - e53830.

89. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late agerelated macular disease // Am J Ophthalmol. - 2004. - Vol. 137, 3. - P. 504-510.

90. Horie-Inoue K, Inoue S. Genomic aspects of age-related macular degeneration // Biochem Biophys Res Commun. - 2014. - Vol. 452, 2. P. 263-275.

91. http://www.snpedia.com.

92. Huang C, Xu Y, Li X, Wang W. Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis // Mol Vis. - 2013. - Vol. 19. - P. 1211-1221.

93. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration // Nat Genet. - 2006. - Vol. 38. - P. 1173-1177.

94. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group // Arch Ophthalmol. - 2000. - Vol. 118, 3. P. 351-358.

95. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration // N Engl J Med. - 2008. - Vol. 358, 24. - P. 2606-2617.

96. Jakobsdottir J, Conley YP, Weeks DE et al. Susceptibility genes for age-related maculopathy on chromosome 10q26 // American Journal of Human Genetics. Vol. 77, 3. - P. 389407.

97. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV.

Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid // Proc Natl Acad Sci USA. - 2006. Vol. 103, 46. P. 7456-7461.

98. Jonasson F, Fisher DE, Eiriksdottir G et al. Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study // Ophthalmology. - 2014. - Vol. 121, 9. - P. 1766-1772.

99. Kaarniranta K1, Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors // J Mol Med (Berl). 2009. Vol. 87, 2. P. 117-123.

100. Kijlstra A, La HE, Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration // Ocul Immunol Inflamm. - 2005.

- Vol. 13. - P. 3-11.

101. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration // Am J Ophthalmol. - 2004. - Vol. 137, 3. - P. 486-495.

102. Klein RJ, Zeiss C, Chew EY et al. Complement Factor H Polymorphism in AgeRelated Macular Degeneration // Science. - 2005. - Vol. 308, 5720. P. 385Kloeckener-Gruissem B, Barthelmes D, Labs S et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD // IOVS. Vol. 52, 7, P. 46944702.

104. Kokotas H, Grigoriadou M, Petersen MB. Age-related macular degeneration:

genetic and clinical findings // Clin Chem Lab Med. - 2011. - Vol. 49, 4. - P.

601-616.

105. Kondo N, Matsui E, Nishimura A, Kaneko H. Pharmacogenetics of asthma in children // Allergy Asthma Immunol Res. - 2010. - Vol. 2, 1. - P. 14-19.

106. Kurihara T, Westenskow PD, Friedlander M. Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina // Adv Exp Med Biol. - 2014. - Vol. 801. - P. 275-281.

107. Lee AY, Raya AK, Kymes SM et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab // British Journal of Ophthalmology. - 2009. -Vol. 9, 5. - P. 610 613.

108. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implimentation // Dialogues Clin Neurosci. - 2006. - P. 8, 1. P.85-94.

109. Lett TA, Wallace TJ, Chowdhury NI et al. Pharmacogenetics of antipsychoticinduced weight gain: review and clinical implications // Mol Psychiatry. - 2012. Vol. 17, 3. - P. 2242-2266.

110. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration // Lancet. - 2012. - Vol. 379. - P. 17281738.

111. Lin JM, Wan L, Tsai YY, et al. Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration // Am J Ophthalmol. - 2008. - Vol. 145, 4. - P. 716-721.

112. Losonczy G, Fekete, Vok Z et al. Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms and ApoE alleles with susceptibility to agerelated macular degeneration in Hungarian patients // Acta Ophthalmol. - 2011. Vol. 89, 3. - P. 255-262.

113. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism // Am J Health Syst Pharm. - 2002. Vol. 59, 21. P. 2061-2069.

114. Magnusson KP, Duan S, Sigurdsson H et al. CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD // PLoS Medicine. - 2006. Vol. 3, 1. - e5.

115. Maller JB, Fagerness JA, Reynolds RC, et al. Variation in complement factor 3 is associated with risk of age-related macular degeneration // Nat Genet. - 2007. Vol. 39, 10. - P. 1200-1201.

116. Manfreda I, Uhlig CE. Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration // Klin Monbl Augenheilkd. - 2010.

- Vol. 227, 8. - P. 657-658.

117. Manunta P, Bianchi G. Pharmacogenomics and pharmacogenetics of hypertension: update and perspectivesthe adducin paradigm // J Am Soc Nephrol. - 2006. - Vol. 17, 4 (Suppl 2). - S30-35.

118. Marn F, Gonzlez-Conejero R, Capranzano P et al. Pharmacogenetics in cardiovascular antithrombotic therapy // J Am Coll Cardiol. - 2009. - Vol. 54, 12. - P. 1041-1057.

119. Mathew R, Sivaprasad S, Florea D, et al. Agreement between time-domain and spectral-domain optical coherence tomography in the assessment of macular thickness in patients with idiopathic macular telangiectasia type 2 // Ophthalmologica. - 2013. Vol. 230, 3. P. 144-150.

120. McKibbin M, Ali M, Bansal S et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration // British Journal of Ophthalmology. - 2012. Vol. 96, 2. P. 208.

121. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics // Pharmacogenomics J. - 2003. - Vol. 3, 4. - P. 197-201.

122. Menghini M, Kurz-Levin MM, Amstutz C et al. Response to ranibizumab therapy in neovascular AMD- An evaluation of good and bad responders // Klinische Monatsblatter fur Augenheilkunde. - 2010. - Vol. 227, 4. - P. 244248.

123. Mitta VP, Christen WG, Glynn RJ, et al. C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts // JAMA Ophthalmol. - 2013.

Vol. 131, 4. - P. 507-513.

124. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by Creactive protein // Immunopharmacology. - 1999. - Vol. 42, 1-3. - P. 23-30.

125. Motulsky AG, Harper PS, Bobrow M, Scriver C. Pharmacogenetics. - New York:

Oxford University Press. 1997. P.199-206.

126. Mller-Eberhard HJ, Schreiber RD. Molecular biology and chemistry of the alternative pathway of complement // Adv Immunol. - 1980. Vol. 29. - P. 1-53.

127. Nischler C, Oberkofler H, Ortner C et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration // Acta Ophthalmologica. - 2011. - Vol. 89, 4. - P. e344 e349.

128. Nita M, Strzaka-Mrozik B, Grzybowski A et al. Age-related macular degeneration and changes in the extracellular matrix // Med Sci Monit. - 2014. Vol. 20. - P. 1003-1016.

129. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy // Pharmacol Rep. - 2006. Vol. 58. - P. 353 363.

130. Oksjoki R. et al. Function and regulation of the complement system in cardiovascular diseases // Front Biosci. - 2007. - Vol. 2. - P. 4696-4708.

131. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine // J Allergy Clin Immunol. Vol. 133, 1. - P. 16-26.

132. O'Shea D, Kim RB, Wilkinson GR. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators // Br J Clin Pharmacol. - 1997. - Vol. 43. 1. - C.

99-103.

133. Ozaki E, Campbell M, Kiang AS et al. Inflammation in age-related macular degeneration // Adv Exp Med Biol. - 2014. - Vol. 801. - P. 229-235.

134. Park SJ, Lee JH, Woo SJ et al. Age-related macular degeneration: prevalence and risk factors from Korean National Health and Nutrition Examination Survey, 2008 through 2011 // Ophthalmology. - 2014. - Vol. 121, 9. - P. 1756-1765.

135. Pascual RM, Bleecker ER. Pharmacogenetics of asthma // Curr Opin Pharmacol. Vol. 10, 3. - P. 226-352.

136. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration // Prog Retin Eye Res. - 2001. - Vol.

20, 3. - P. 385-414.

137. Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation // Clin Pharmacol Ther. - 2014. - Vol. 95, 2. - P. 199-207.

138. Preissner SC, Hoffmann MF et al. Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy // PLoS One. - 2013. Vol. 8, 12. - e82562.

139. Robman L, Baird PN, Dimitrov PN et al. C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression // Ophthalmology. - 2010. - Vol. 117, 10. - P.

1982-1988.

140. Ross CJ, Visscher H, Sistonen J, et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology // Thyroid. 2010. Vol. 20, 7. - P. 681-687.

141. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease // Graefes Arch Clin Exp Ophthalmol. - 2004. - Vol. 242, 8. P. 710-716.

142. Rudnicka AR, Kapetanakis VV, Jarrar Z et al. Incidence of Late-Stage AgeRelated Macular Degeneration in American Whites: Systematic Review and Meta-analysis // Am J Ophthalmol. - 2015. - Vol. 160, 1. - P. 85-93.

143. Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2a receptor gene and response to latanoprost // Ophthalmology. - 2007. Vol. 114, 6. - P. 10391045.

144. Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis // J Pharmacol Exp Ther. - 1976. Vol. 197. P. 7988.

145. Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol // Acta Ophthalmol Suppl. - 1985. - Vol.

173. P. 1518.

146. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

// Ophthalmology. - 2008. - Vol. 115, 1. - P. 2199-2205.

147. Schaumberg DA, Christen WG, Kozlowski P, et al. A prospective assessment of the Y402H variant in complement factor H, genetic variants in c-reactive protein, and risk of age-related macular degeneration. // IOVS. - 2006. Vol. 47. P.

23362340.

148. Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. 1-Adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers // Ophthalmology. - 2005. Vol. 112, 12. - P. 21312136.

149. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of agerelated macular degeneration: relative roles of genetic and environmental influences // Arch Ophthal. - 2005. - Vol. 123. - P. 321-327.

150. Seddon JM, Gensler G, Milton RC. Association between C-reactive protein and age-related macular degeneration // JAMA. - 2004. Vol. 291, 6. - P. 704-710.

151. Shastry BS. Genetic diversity and medicinal drug response in eye care // Graefes Arch Clin Exp Ophthalmol. - 2010. - Vol. 248, 8. - P. 1057-1061.

152. Shuldiner AR, Palmer K, Pakyz RE et al. Implementation of pharmacogenetics:

the University of Maryland Personalized Anti-platelet Pharmacogenetics Program // Am J Med Genet C Semin Med Genet. - 2014. - Vol. 166C, 1. - P. 76-84.

153. Silva AS, Teixeira AG, Bavia L et al. Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H TyrHis polymorphism // Mol Vis. Vol. 18. - P. 2288-2299.

154. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents // Ophthalmology. - 2001. Vol. 108. - P. 697704.

155. Sobrin L, Reynolds R, Yu Y et al. ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration // Am J Ophthalmol. - 2011. - Vol. 151, 2. - P. 345-352.

156. Soh TI, Yong WP, Innocenti F. Recent progress and clinical importance on pharmacogenetics in cancer therapy // Clin Chem Lab Med. - 2011. Vol. 49, 10. - P. 1621-1632.

157. Sparrow JR, Ueda K, Zhou J. Complement dysregulation in AMD: RPE-Bruch's membrane-choroid // Mol Aspects Med. - 2012. - Vol. 33, 4. - P. 436-445.

158. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration // Hum Mol Genet. 2007. - Vol. 16, 16. - P. 1986-1992.

159. Stanton CM, Wright AF. Inflammatory biomarkers for AMD // Adv Exp Med Biol. - 2014. - Vol. 801. - P. 251-257.

160. Telander DG. Inflammation and age-related macular degeneration (AMD) // Semin Ophthalmol. - 2011. - Vol. 26, 3. - P. 192-197.

161. Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration // Molecular Vision. - 2010. - Vol. 16. - P.

25982604.

162. Thakkinstian A, Han P, McEvoy M, Smith W et al. Systematic review and metaanalysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration // Human Molecular Genetics. 2006. Vol. 15. P. 27842790.

163. Tsai Yi-Yu, Lin Jane-Ming, Wan Lei. Interleukin Gene Polymorphisms in AgeRelated Macular Degeneration // IOVS. - 2008. - Vol. 49, 2. P. 693-698.

164. Tzvetkov M, von Ahsen N. Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era // Pathology. - 2012. - Vol. 44, 2. - P. 166-180.

165. Ueta T, Noda Y, Toyama T et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials // Ophthalmology. - 2014. - Vol. 121, 11. - P. 2193-2203.

166. Urban TJ, Goldstein DB. Pharmacogenetics at 50: genomic personalization comes of age // Sci Transl Med. - 2014. Vol. 6, 220. P. 220ps1.

167. Wang J, Pang GS, Chong SS, Lee CG. SNP web resources and their potential applications in personalized medicine // Curr Drug Metab. - 2012. - Vol. 13, 7.

- P. 978-990.

168. Wang X, Zhang Y, Zhang MN. Complement factor B polymorphism (rs641153) and susceptibility to age-related macular degeneration: evidence from published studies // Int J Ophthalmol. - 2013. - Vol. 6, 6. - P. 861-867.

169. Weber B, Issa PC, Pauly D et al. The Role of the Complement System in AgeRelated Macular Degeneration // Dtsch Arztebl Int. - 2014. - Vol. 111, 8. - P.

133138.

170. Weger M, Renner W, Steinbrugger I. Association of the HTRA1 -625GA promoter gene polymorphism with exudative age-related macular degeneration in a Central European population // Molecular Vision. - 2007. Vol. 13. P. 1274Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment // Pharmacogenomics J. - 2006. - Vol. 6, 5. P. 311-326.

172. Werb Z, Gordon S. Secretion of a specific collagenase by stimulated macrophages // J Exp Med. - 1975. - Vol. 142. - P. 346-360.

173. Wickremasinghe SS, Xie J, Lim J et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD // IOVS. - 2011. - Vol. 52, 7. P. 40724079.

174. Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis // Lancet Glob Health. - 2014. - Vol. 2, 2. - P. e106Yang Y, Peter I, Scott SA. Pharmacogenetics in Jewish populations // Drug Metabol Drug Interact. - 2014. - Vol. 29, 4. - P. 221-233.

176. Yang Z, Camp NJ, Tong HSZ et al. A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration // Science. - 2006. - Vol.

314. P. 992-993.

177. Yang Z, Tong Z, Chen Y et al. Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration // PLoS Genet. - 2010. Vol. 6, 2. P. e1000836.

178. 179Yates JR, Sepp T, Matharu BK et al. Complement C3 variant and the risk of age-related macular degeneration // New England Journal of Medicine. - 2007. Vol. 357, 6, P. 553561.

179. 180Yu W, Dong S, Zhao C et al. Cumulative association between age-related macular degeneration and less studied genetic variants in PLEKHA1/ARMS2/HTRA1: a meta and gene-cluster analysis // Mol Biol Rep. Vol. 40, 10. - P. 5551-5561.

180. 181Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration // Arch Ophthalmol. - 2004. - Vol. 122, 4. - Vol. 598-614.

181. 182Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma // Nat Rev Drug Discov. Vol. 11. - P. 541-559.

182. 183Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact // Drug Metab Rev. - 2009. Vol. 41, 2. P.

89-295.



Pages:     | 1 |   ...   | 2 | 3 ||

:

03.02.10 ...

03.01.03 : ...

- - 03.02.08 ( ) : ...

- 14.01.07 ...

: 06.02.02 , , , :...

- PICEA PUNGENS ENGL. P. OBOVATA LEDEB. (. ) 03.02.08 ( ) : ...

5 ( ) 03.03.02 : , .-. .. ...

14.02.01 : , ...

() - 03.03.04 , , ...

13.00.01 , ...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .